279 research outputs found

    Star Formation History of a Young Super-Star Cluster in NGC 4038/39: Direct Detection of Low Mass Pre-Main Sequence Stars

    Get PDF
    We present an analysis of the near-infrared spectrum of a young massive star cluster in the overlap region of the interacting galaxies NGC 4038/39 using population synthesis models. Our goal is to model the cluster population as well as provide rough constraints on its initial mass function (IMF). The cluster shows signs of youth such as thermal radio emission and strong hydrogen emission lines in the near-infrared. Late-type absorption lines are also present which are indicative of late-type stars in the cluster. The strength and ratio of these absorption lines cannot be reproduced through either late-type pre-main sequence (PMS) stars or red supergiants alone. Thus we interpret the spectrum as a superposition of two star clusters of different ages, which is feasible since the 1" spectrum encompasses a physical region of ~90 pc and radii of super-star clusters are generally measured to be a few parsecs. One cluster is young (<= 3 Myr) and is responsible for part of the late-type absorption features, which are due to PMS stars in the cluster, and the hydrogen emission lines. The second cluster is older (6 Myr - 18 Myr) and is needed to reproduce the overall depth of the late-type absorption features in the spectrum. Both are required to accurately reproduce the near-infrared spectrum of the object. Thus we have directly detected PMS objects in an unresolved super-star cluster for the first time using a combination of population synthesis models and pre-main sequence tracks. This analysis serves as a testbed of our technique to constrain the low-mass IMF in young super-star clusters as well as an exploration of the star formation history of young UC HII regions.Comment: 26 pages, 5 figures, accepted for publication in the Astrophysical Journa

    Olivine-rich exposures at Bellicia and Arruntia craters on (4) Vesta from Dawn FC

    Full text link
    We present an analysis of the olivine-rich exposures at Bellicia and Arruntia craters using Dawn Framing Camera (FC) color data. Our results confirm the existence of olivine-rich materials at these localities as described by Ammannito et al. (2013a) using Visual Infrared Spectrometer (VIR) data. Analyzing laboratory spectra of various Howardite-Eucrite-Diogenite meteorites, high-Ca pyroxenes, olivines and olivine-orthopyroxene mixtures, we derive three FC spectral band parameters that are indicators of olivine-rich materials. Combining the three band parameters allows us, for the first time, to reliably identify sites showing modal olivine contents >40%. The olivine-rich exposures at Bellicia and Arruntia are mapped using higher spatial resolution FC data. The exposures are located on the slopes of outer/inner crater walls, on the floor of Arruntia, in the ejecta, as well as in nearby fresh small impact craters. The spatial extent of the exposures ranges from a few hundred meters to few kilometers. The olivine-rich exposures are in accordance with both the magma ocean and the serial magmatism model (e.g., Righter and Drake 1997; Yamaguchi et al. 1997). However, it remains unsolved why the olivine-rich materials are mainly concentrated in the northern hemisphere (~36-42{\deg} N, 46-74{\deg} E) and are almost absent in the Rheasilvia basin.Comment: Accepted for publication in Meteoritics and Planetary Scienc

    Efficacy and outcome of expanded newborn screening for metabolic diseases - Report of 10 years from South-West Germany *

    Get PDF
    <p>Abstract</p> <p>Background</p> <p>National newborn screening programmes based on tandem-mass spectrometry (MS/MS) and other newborn screening (NBS) technologies show a substantial variation in number and types of disorders included in the screening panel. Once established, these methods offer the opportunity to extend newborn screening panels without significant investment and cost. However, systematic evaluations of newborn screening programmes are rare, most often only describing parts of the whole process from taking blood samples to long-term evaluation of outcome.</p> <p>Methods</p> <p>In a prospective single screening centre observational study 373 cases with confirmed diagnosis of a metabolic disorder from a total cohort of 1,084,195 neonates screened in one newborn screening laboratory between January 1, 1999, and June 30, 2009 and subsequently treated and monitored in five specialised centres for inborn errors of metabolism were examined. Process times for taking screening samples, obtaining results, initiating diagnostic confirmation and starting treatment as well as the outcome variables metabolic decompensations, clinical status, and intellectual development at a mean age of 3.3 years were evaluated.</p> <p>Results</p> <p>Optimal outcome is achieved especially for the large subgroup of patients with medium-chain acyl-CoA dehydrogenase deficiency. Kaplan-Meier-analysis revealed disorder related patterns of decompensation. Urea cycle disorders, organic acid disorders, and amino acid disorders show an early high and continuous risk, medium-chain acyl-CoA dehydrogenase deficiency a continuous but much lower risk for decompensation, other fatty acid oxidation disorders an intermediate risk increasing towards the end of the first year. Clinical symptoms seem inevitable in a small subgroup of patients with very early disease onset. Later decompensation can not be completely prevented despite pre-symptomatic start of treatment. Metabolic decompensation does not necessarily result in impairment of intellectual development, but there is a definite association between the two.</p> <p>Conclusions</p> <p>Physical and cognitive outcome in patients with presymptomatic diagnosis of metabolic disorders included in the current German screening panel is equally good as in phenylketonuria, used as a gold standard for NBS. Extended NBS entails many different interrelated variables which need to be carefully evaluated and optimized. More reports from different parts of the world are needed to allow a comprehensive assessment of the likely benefits, harms and costs in different populations.</p

    A cross‐sectional, prospective ocular motor study in 72 patients with Niemann‐Pick disease type C

    Get PDF
    Objective: To characterize ocular motor function in patients with Niemann-Pick disease type C (NPC). Methods: In a multicontinental, cross-sectional study we characterized ocular-motor function in 72 patients from 12 countries by video-oculography. Interlinking with disease severity, we also searched for ocular motor biomarkers. Our study protocol comprised reflexive and self-paced saccades, smooth pursuit, and gaze-holding in horizontal and vertical planes. Data were compared with those of 158 healthy controls (HC). Results: Some 98.2% of patients generated vertical saccades below the 95% CI of the controls' peak velocity. Only 46.9% of patients had smooth pursuit gain lower than that of 95% CI of HC. The involvement in both downward and upward directions was similar (51°/s (68.9, [32.7-69.3]) downward versus 78.8°/s (65.9, [60.8-96.8]) upward). Horizontal saccadic peak velocity and latency, vertical saccadic duration and amplitude, and horizontal position smooth pursuit correlated best to disease severity. Compensating strategies such as blinks to elicit saccades, and head and upper body movements to overcome the gaze palsy, were observed. Vertical reflexive saccades were more impaired and slower than self-paced ones. Gaze-holding was normal. Ocular-motor performance depended on the age of onset and disease duration. Conclusions: This is the largest cohort of NPC patients investigated for ocular-motor function. Vertical supranuclear saccade palsy is the hallmark of NPC. Vertical upward and downward saccades are equally impaired. Horizontal saccadic peak velocity and latency, vertical saccadic duration and amplitude, and horizontal position smooth pursuit can be used as surrogate parameters for clinical trials. Compensating strategies can contribute to establishing a diagnosis

    Functional and genetic characterization of the non-lysosomal glucosylceramidase 2 as a modifier for Gaucher disease

    Get PDF
    Background: Gaucher disease (GD) is the most common inherited lysosomal storage disorder in humans, caused by mutations in the gene encoding the lysosomal enzyme glucocerebrosidase (GBA1). GD is clinically heterogeneous and although the type of GBA1 mutation plays a role in determining the type of GD, it does not explain the clinical variability seen among patients. Cumulative evidence from recent studies suggests that GBA2 could play a role in the pathogenesis of GD and potentially interacts with GBA1. Methods: We used a framework of functional and genetic approaches in order to further characterize a potential role of GBA2 in GD. Glucosylceramide (GlcCer) levels in spleen, liver and brain of GBA2-deficient mice and mRNA and protein expression of GBA2 in GBA1-deficient murine fibroblasts were analyzed. Furthermore we crossed GBA2-deficient mice with conditional Gba1 knockout mice in order to quantify the interaction between GBA1 and GBA2. Finally, a genetic approach was used to test whether genetic variation in GBA2 is associated with GD and/or acts as a modifier in Gaucher patients. We tested 22 SNPs in the GBA2 and GBA1 genes in 98 type 1 and 60 type 2/3 Gaucher patients for single-and multi-marker association with GD. Results: We found a significant accumulation of GlcCer compared to wild-type controls in all three organs studied. In addition, a significant increase of Gba2-protein and Gba2-mRNA levels in GBA1-deficient murine fibroblasts was observed. GlcCer levels in the spleen from Gba1/Gba2 knockout mice were much higher than the sum of the single knockouts, indicating a cross-talk between the two glucosylceramidases and suggesting a partially compensation of the loss of one enzyme by the other. In the genetic approach, no significant association with severity of GD was found for SNPs at the GBA2 locus. However, in the multi-marker analyses a significant result was detected for p.L444P (GBA1) and rs4878628 (GBA2), using a model that does not take marginal effects into account. Conclusions: All together our observations make GBA2 a likely candidate to be involved in GD etiology. Furthermore, they point to GBA2 as a plausible modifier for GBA1 in patients with GD

    Rationale and design of the RIACT–study: a multi-center placebo controlled double blind study to test the efficacy of RItuximab in Acute Cellular tubulointerstitial rejection with B-cell infiltrates in renal Transplant patients: study protocol for a randomized controlled trial

    Get PDF
    BACKGROUND: Acute kidney allograft rejection is a major cause for declining graft function and has a negative impact on the long-term graft survival. The majority (90%) of acute rejections are T-cell mediated and, therefore, the anti-rejection therapy targets T-cell-mediated mechanisms of the rejection process. However, there is increasing evidence that intragraft B-cells are also important in the T-cell-mediated rejections. First, a significant proportion of patients with acute T-cell-mediated rejection have B-cells present in the infiltrates. Second, the outcome of these patients is inferior, which has been related to an inferior response to the conventional anti-rejection therapy. Third, treatment of these patients with an anti-CD20 antibody (rituximab) improves the allograft outcome as reported in single case observations and in one small study. Despite the promise of these observations, solid evidence is required before incorporating this treatment option into a general treatment recommendation. METHODS/DESIGN: The RIACT study is designed as a randomized, double-blind, placebo-controlled, parallel group multicenter Phase III study. The study examines whether rituximab, in addition to the standard treatment with steroid-boli, leads to an improved one-year kidney allograft function, compared to the standard treatment alone in patients with acute T-cell mediated tubulointerstitial rejection and significant B-cell infiltrates in their biopsies. A total of 180 patients will be recruited. DISCUSSION: It is important to clarify the relevance of anti-B cell targeting in T-cell mediated rejection and answer the question whether this novel concept should be incorporated in the conventional anti-rejection therapy. TRIAL REGISTRATION: Clinical trials gov. number: NCT0111766
    • 

    corecore